2019 FDA Approved Drugs
The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale
in the United States. Drug information typically includes the drug name, approval status, indication of use, and
clinical trial results.
Review descriptions for our medical therapeutic area list to help
assist in your search.
Join our Drug Research Updates group on LinkedIn!
Find out more about the types of drugs included in this listing.
Dermatology
Jeuveau (prabotulinumtoxinA-xvfs); Evolus;
For the improvement of glabellar lines, Approved February 2019
Family Medicine
Tosymra (sumatriptan nasal spray); Dr. Reddy's Labs;
For the treatment of acute migraine in adults, Approved January 2019
Hematology
Cablivi (caplacizumab-yhdp); Ablynx;
For the treatment of acquired thrombotic thrombocytopenic purpura, Approved February 2019
Neurology
Tosymra (sumatriptan nasal spray); Dr. Reddy's Labs;
For the treatment of acute migraine in adults, Approved January 2019
The criteria for CenterWatch's FDA-Approved Drugs follow the definitions established by the Tufts Center for the Study of Drug Development and the FDA's definitions of a new drug approval or a new molecular entity.
Database inclusions:
New Molecular Entities (NME) is defined by the FDA as a medication containing an active substance that has never before been approved for marketing in any form in the United States. The database also includes some recombinant proteins and biologics that were approved by the FDA's Center for Drug Evaluation and Research (CDER).
Database exclusions:
Diagnostic agents, generics, over-the-counter products, medical devices, and biologic compounds not approved by CDER. Other exclusions are new dosages and new administrations of previously-approved compounds.
